长春新碱在骨髓瘤诱导和维持治疗中作用的客观评估。医学研究委员会成人白血病工作组。
Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults.
作者信息
MacLennan I C, Cusick J
出版信息
Br J Cancer. 1985 Aug;52(2):153-8. doi: 10.1038/bjc.1985.171.
Abstract
In the Medical Research Council's IVth trial in Myelomatosis the possible benefit of adding vincristine to first line treatment with intermittent melphalan and prednisone has been assessed. This was analysed in 530 patients who were randomly allocated to receive vincristine or not. Survival was not improved by the addition of vincristine. A total of 268 patients reached plateau phase on first line therapy. Of these 226 patients were rerandomised either to continue receiving first line therapy for a further year or to cease therapy. At the present time there is a slight but not significant survival advantage in the group which received no further treatment on reaching plateau.
摘要
在医学研究委员会关于骨髓瘤的第四次试验中，评估了在间歇使用美法仑和泼尼松进行一线治疗时添加长春新碱可能带来的益处。对530名随机分配接受或不接受长春新碱治疗的患者进行了分析。添加长春新碱并未改善生存率。共有268名患者在一线治疗时进入平台期。其中226名患者被重新随机分组，要么继续接受一线治疗一年，要么停止治疗。目前，在达到平台期后不再接受进一步治疗的组中，有轻微但不显著的生存优势。
相似文献
1
Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults.长春新碱在骨髓瘤诱导和维持治疗中作用的客观评估。医学研究委员会成人白血病工作组。
Br J Cancer. 1985 Aug;52(2):153-8. doi: 10.1038/bjc.1985.171.
2
Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults.联合使用ABCM与美法仑进行化疗治疗骨髓瘤。成人白血病医学研究委员会工作组。
Lancet. 1992 Jan 25;339(8787):200-5. doi: 10.1016/0140-6736(92)90004-m.
3
Treatment comparisons in the third MRC myelomatosis trial. Medical Research Council's Working Party on Leukaemia in Adults.第三届医学研究委员会骨髓瘤病试验中的治疗对比。医学研究委员会成人白血病工作组。
Br J Cancer. 1980 Dec;42(6):823-30. doi: 10.1038/bjc.1980.329.
4
Report on the second myelomatosis trial after five years of follow-up. Medical Research Council's Working Party on Leukaemia in Adults.成人白血病医学研究委员会工作组：五年随访后第二次骨髓瘤病试验报告。
Br J Cancer. 1980 Dec;42(6):813-22. doi: 10.1038/bjc.1980.328.
5
Standard-dose therapy for multiple myeloma: The Southwest Oncology Group experience.多发性骨髓瘤的标准剂量疗法：西南肿瘤协作组的经验
Semin Hematol. 2001 Jul;38(3):203-8. doi: 10.1016/s0037-1963(01)90011-3.
6
Remission maintenance therapy for multiple myeloma.多发性骨髓瘤的缓解维持治疗
Arch Intern Med. 1975 Jan;135(1):147-52.
7
Results and further perspectives of plasmocytoma chemotherapy.
Neoplasma. 1986;33(2):251-8.
8
Treatment of multiple myeloma: 2009 update.多发性骨髓瘤的治疗：2009年更新
Prescrire Int. 2009 Dec;18(104):263-6.
9
Vincristine and prednisone prolong the survival of patients receiving intravenous or oral melphalan for multiple myeloma: Cancer and Leukemia Group B experience.长春新碱和泼尼松可延长接受静脉或口服美法仑治疗的多发性骨髓瘤患者的生存期：癌症与白血病B组的经验。
J Clin Oncol. 1988 Sep;6(9):1481-90. doi: 10.1200/JCO.1988.6.9.1481.
10
Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study.多发性骨髓瘤联合化疗诱导改善生存时间：西南肿瘤协作组研究
J Clin Oncol. 1986 Aug;4(8):1227-37. doi: 10.1200/JCO.1986.4.8.1227.
引用本文的文献
1
Secondary primary malignancies in multiple myeloma: an old NEMESIS revisited.多发性骨髓瘤中的继发性原发性恶性肿瘤：重温古老的难题
Adv Hematol. 2012;2012:801495. doi: 10.1155/2012/801495. Epub 2012 Jul 19.
2
Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. The Cooperative Group of Study and Treatment of Multiple Myeloma.晚期骨髓瘤低骨髓抑制化疗方案的经验。多发性骨髓瘤研究与治疗协作组。
Br J Cancer. 1996 Mar;73(6):794-7. doi: 10.1038/bjc.1996.138.
3
Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma.根据疾病分期治疗多发性骨髓瘤：一项前瞻性随机研究，比较较温和与更积极的细胞周期抑制策略。多发性骨髓瘤研究与治疗协作组
Br J Cancer. 1994 Dec;70(6):1203-10. doi: 10.1038/bjc.1994.474.
4
Selective induction of light chain synthesis in cultures of blood lymphocytes from patients with IgG myelomatosis.IgG 骨髓瘤患者血淋巴细胞培养物中轻链合成的选择性诱导。
Clin Exp Immunol. 1988 Jan;71(1):193-7.
5
Intrathecal vincristine: a fatal chemotherapeutic error with devastating central nervous system effects.鞘内注射长春新碱：一种导致毁灭性中枢神经系统效应的致命化疗错误。
J Neurol. 1991 Jul;238(4):230-4. doi: 10.1007/BF00314787.
本文引用的文献
1
Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience.口服美法仑、洛莫司汀和卡莫司汀联合或不联合长春新碱及泼尼松治疗多发性骨髓瘤的比较。癌症与白血病B组的经验。
Cancer. 1982 Nov 1;50(9):1669-75. doi: 10.1002/1097-0142(19821101)50:9<1669::aid-cncr2820500902>3.0.co;2-n.
2
Treatment of multiple myeloma with M-2 protocol and without maintenance therapy.采用M-2方案且无维持治疗的多发性骨髓瘤治疗
Eur J Cancer Clin Oncol. 1983 Oct;19(10):1345-51. doi: 10.1016/0277-5379(93)90002-m.
3
Effective treatment of advanced multiple myeloma refractory to alkylating agents.对烷化剂难治的晚期多发性骨髓瘤的有效治疗。
N Engl J Med. 1984 May 24;310(21):1353-6. doi: 10.1056/NEJM198405243102104.
4
Chemotherapy for multiple myeloma.多发性骨髓瘤的化疗
Cancer. 1984 Feb 1;53(3):583-8. doi: 10.1002/1097-0142(19840201)53:3<583::aid-cncr2820530336>3.0.co;2-1.
5
Proximal renal tubular function in myelomatosis: observations in the fourth Medical Research Council trial.骨髓瘤病中的近端肾小管功能：医学研究委员会第四次试验中的观察结果
J Clin Pathol. 1984 Aug;37(8):852-8. doi: 10.1136/jcp.37.8.852.
6
Addition of cisplatin and bleomycin to vincristine-carmustine-doxorubicin-prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study.在长春新碱-卡莫司汀-阿霉素-泼尼松（VBAP）联合方案基础上加用顺铂和博来霉素治疗复发或耐药性多发性骨髓瘤：一项西南肿瘤协作组研究
Cancer Treat Rep. 1984 Mar;68(3):481-5.
7
Proceedings: Combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone, and BCNU.研究报告：美法仑、环磷酰胺、长春新碱、泼尼松和卡氮芥联合化疗多发性骨髓瘤
Cancer. 1974 Feb;33(2):533-8. doi: 10.1002/1097-0142(197402)33:2<533::aid-cncr2820330231>3.0.co;2-z.
8
Tumor growth patterns in multiple myeloma.多发性骨髓瘤中的肿瘤生长模式。
Cancer. 1977 Mar;39(3):1077-84. doi: 10.1002/1097-0142(197703)39:3<1077::aid-cncr2820390311>3.0.co;2-s.
9
Expansion of the growth fraction in multiple myeloma with alkylating agents.烷化剂对多发性骨髓瘤中增殖分数的影响。
Blood. 1975 Jan;45(1):119-29.
10
Unmaintained remissions in multiple myeloma.多发性骨髓瘤的未维持缓解
Blood. 1978 Jun;51(6):1005-11.
Zotero 插件